Consistent with the therapeutic effect reflected by BLI, the volumes and masses of tumours treated with cocultured CD8+ T cells combined with CAR NK‐92 and atezolizumab or nivolumab decreased significantly compared to those of tumours treated with combined therapy without ICI (Figure 6G–I). This evidence concerns the gene CD8A and neoplasm.